Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment naive adults.

Supplementary material

Figure 1: Weight distribution among individuals starting efavirenz in different calendar periods.

N, total number of individuals per calendar periods.
Figure 2: Kaplan-Meier curves for virological outcomes according to the various body weight groups, a) initial virological suppression after treatment initiation and b) virological rebound after achieving initial suppression.
b) Video abstract